US equities |
MU $1,029.00 ▲+0.00% SNDK $1,581.82 ▲+0.00% NVDA $229.28 ▲+0.00% INTC $104.70 ▲+0.00% META $718.67 ▲+0.00% SPCX $162.57 ▲+0.00% TSLA $382.70 ▲+0.00% IREN $35.19 ▲+0.00%
FinancialContent

Tectonic Therapeutic, Inc. - Common Stock (NQ:TECX)

23.33 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tectonic Therapeutic, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic to Participate in March Investor Conferences
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic to Participate in December Investor Conferences
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic to Participate in September Investor Conferences
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Joins Russell 3000® Index
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic to Present Phase 1b Data for TX45 at European Society of Cardiology Heart Failure 2025
Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohort 
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic to Participate in March Investor Conferences
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Announces $185 Million Private Placement
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Announces Positive Interim Data from Phase 1b Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic to Host KOL Event on the Unmet Need in Group 2 PH-HFpEF and TX45 as a Potential Treatment on Thursday, December 12, 2024
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic To Present on December 3rd, 2024 at the Piper Sandler Healthcare Conference
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Announces Third Quarter 2024 Financial Results and Recent Business Highlights
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic to Present Phase 1a Data at AHA 2024
American Heart Association (AHA) poster to be presented on November 16, 2024 
From Tectonic Therapeutic
Via GlobeNewswire
News headline image
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
From Tectonic Therapeutic
Via GlobeNewswire
< Previous 1 2 Next >